<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Death Discov</journal-id><journal-id journal-id-type="iso-abbrev">Cell Death Discov</journal-id><journal-title-group><journal-title>Cell Death Discovery</journal-title></journal-title-group><issn pub-type="epub">2058-7716</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39730333</article-id><article-id pub-id-type="pmc">PMC11681259</article-id><article-id pub-id-type="publisher-id">2277</article-id><article-id pub-id-type="doi">10.1038/s41420-024-02277-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Mitochondria-targeted antioxidant MitoQ radiosensitizes tumors by decreasing mitochondrial oxygen consumption</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0009-0003-1239-4633</contrib-id><name><surname>Rondeau</surname><given-names>Justin D.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0009-0008-4058-7922</contrib-id><name><surname>Lipari</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3398-5144</contrib-id><name><surname>Mathieu</surname><given-names>Barbara</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4678-6865</contrib-id><name><surname>Beckers</surname><given-names>Claire</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0054-9020</contrib-id><name><surname>Van de Velde</surname><given-names>Justine A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9426-8600</contrib-id><name><surname>Mignion</surname><given-names>Lionel</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7718-1629</contrib-id><name><surname>Da Silva Morais</surname><given-names>Mauricio</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kreuzer</surname><given-names>Marvin</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0009-0008-0191-1769</contrib-id><name><surname>Colauzzi</surname><given-names>Ilaria</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Capeloa</surname><given-names>Tania</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3124-9015</contrib-id><name><surname>Pruschy</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5708-1302</contrib-id><name><surname>Gallez</surname><given-names>Bernard</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Sonveaux</surname><given-names>Pierre</given-names></name><address><email>pierre.sonveaux@uclouvain.be</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02495e989</institution-id><institution-id institution-id-type="GRID">grid.7942.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 2294 713X</institution-id><institution>Pole of Pharmacology and Therapeutics, Institut de Recherche Exp&#x000e9;rimentale et Clinique (IREC), </institution><institution>Universit&#x000e9; catholique de Louvain (UCLouvain), </institution></institution-wrap>Brussels, Belgium </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02495e989</institution-id><institution-id institution-id-type="GRID">grid.7942.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 2294 713X</institution-id><institution>Biomedical Magnetic Resonance Research Group, Louvain Drug Research Institute (LDRI), </institution><institution>UCLouvain, </institution></institution-wrap>Brussels, Belgium </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02crff812</institution-id><institution-id institution-id-type="GRID">grid.7400.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0650</institution-id><institution>Laboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, </institution><institution>University of Zurich, </institution></institution-wrap>Zurich, Switzerland </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02495e989</institution-id><institution-id institution-id-type="GRID">grid.7942.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 2294 713X</institution-id><institution>Nuclear and Electron Spin Technologies (NEST) Platform, LDRI, </institution><institution>UCLouvain, </institution></institution-wrap>Brussels, Belgium </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04qbvw321</institution-id><institution-id institution-id-type="GRID">grid.509491.0</institution-id><institution>WEL Research Institute, </institution><institution>WELBIO Department, </institution></institution-wrap>Wavre, Belgium </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>10</volume><elocation-id>514</elocation-id><history><date date-type="received"><day>2</day><month>9</month><year>2024</year></date><date date-type="rev-recd"><day>10</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>17</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Hypoxic tumors are radioresistant stemming from the fact that oxygen promotes reactive oxygen species (ROS) propagation after water radiolysis and stabilizes irradiation-induced DNA damage. Therefore, an attractive strategy to radiosensitize solid tumors is to increase tumor oxygenation at the time of irradiation, ideally above a partial pressure of 10 mm-Hg at which full radiosensitization can be reached. Historically, the many attempts to increase vascular O<sub>2</sub> delivery have had limited efficacy, but mathematical models predicted that inhibiting cancer cell respiration would be more effective. Here, we report that mitochondria-targeted antioxidant MitoQ can radiosensitize human breast tumors in mice. This was not a class effect, as neither MitoTEMPO nor SKQ1 shared this property. At clinically relevant nanomolar concentrations, MitoQ completely abrogated the oxygen consumption of several human cancer cell lines of different origins, which was associated with a glycolytic switch. Using orthotopic breast cancer models in mice, we observed that pretreating hypoxic MDA-MB-231 tumors with MitoQ delayed tumor growth with both single dose irradiation and clinically relevant fractionated radiotherapy. Oxygenated MCF7 tumors were not radiosensitized, suggesting an oxygen enhancement effect of MitoQ. Because MitoQ already successfully passed Phase I clinical trials, our findings foster its clinical evaluation in combination with radiotherapy.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Radiotherapy</kwd><kwd>Cancer metabolism</kwd><kwd>Cancer microenvironment</kwd><kwd>Breast cancer</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100011264</institution-id><institution>EC | EC Seventh Framework Programm | FP7 People: Marie-Curie Actions (FP7-PEOPLE - Specific Programme "People" Implementing the Seventh Framework Programme of the European Community for Research, Technological Development and Demonstration Activities (2007 to 2013))</institution></institution-wrap></funding-source><award-id>860245 THERADNET</award-id><award-id>860245 THERADNET</award-id><award-id>860245 THERADNET</award-id><award-id>860245 THERADNET</award-id><award-id>860245 THERADNET</award-id><award-id>860245 THERADNET</award-id><award-id>860245 THERADNET</award-id><principal-award-recipient><name><surname>Rondeau</surname><given-names>Justin D.</given-names></name><name><surname>Lipari</surname><given-names>Sara</given-names></name><name><surname>Beckers</surname><given-names>Claire</given-names></name><name><surname>Kreuzer</surname><given-names>Marvin</given-names></name><name><surname>Colauzzi</surname><given-names>Ilaria</given-names></name><name><surname>Pruschy</surname><given-names>Martin</given-names></name><name><surname>Sonveaux</surname><given-names>Pierre</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100002661</institution-id><institution>Fonds De La Recherche Scientifique - FNRS (Belgian National Fund for Scientific Research)</institution></institution-wrap></funding-source><award-id>CDR J.0177.22</award-id><principal-award-recipient><name><surname>Sonveaux</surname><given-names>Pierre</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100007355</institution-id><institution>Fondation Louvain (Louvain Foundation)</institution></institution-wrap></funding-source><award-id>N/A</award-id><principal-award-recipient><name><surname>Sonveaux</surname><given-names>Pierre</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Communaute francaise de Belgique ARC 21/26-118 R&#x000e9;gion wallonne de Belgique - Wallonie Recherche SPW BEWARE2 2210063</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Cell Death Differentiation Association (ADMC) 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Solid tumors are metabolically heterogeneous, comprising oxidative and glycolytic cancer and host cells. Oxidative cancer cells are typically located close to perfused blood vessels carrying oxygenated red blood cells (RBCs). They are metabolically flexible, using a variety of substrates to fuel the tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS) within mitochondria [<xref ref-type="bibr" rid="CR1">1</xref>]. Comparatively, glycolytic cancer cells primarily populate hypoxic tumor areas, and further comprise proliferating cancer cells that are glycolytic independently of the local partial pressure of oxygen (pO<sub>2</sub>) (the Warburg phenotype) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. These cells have less metabolic flexibility because they depend on glucose as an obligatory substrate, but maintain metabolic plasticity as glycolytic and oxidative phenotypes are timely and spatially interchangeable with respect to variations in tumor microenvironment composition [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par3">Tumor hypoxia has long been recognized as a major factor limiting cancer cell sensitivity to photon radiotherapy (X- and &#x003b3;-rays) [<xref ref-type="bibr" rid="CR4">4</xref>]. It is generally understood that full radiosensitivity can be achieved at a pO<sub>2</sub>&#x02009;&#x0003e;&#x02009;10 mm-Hg, with cancer cells at lower pO<sub>2</sub> levels being increasingly radioresistant [<xref ref-type="bibr" rid="CR5">5</xref>]. Molecularly, the oxygen enhancement effect (OEE) reflects the involvement of O<sub>2</sub> in the production and propagation of reactive oxygen species (ROS) following water radiolysis and the ability of O<sub>2</sub> to stabilize radicals on DNA to produce DNA peroxides [<xref ref-type="bibr" rid="CR4">4</xref>]. The radiobiological community has therefore deployed intense efforts to find appropriate ways to increase tumor oxygenation at the time of therapeutic irradiation, although with limited success [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Among all attempts, only non-invasive hyperthermia, which improves tumor perfusion and inhibits DNA repair, reached clinical use [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par4">As an alternative (or in addition) to increasing tumoral oxygen delivery, inhibiting OXPHOS in tumors could also result in enhanced tumor oxygenation at the time of irradiation. According to mathematical models developed by the group of Mark W. Dewhirst [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>], this strategy is in theory the most effective way to radiosensitize tumors through the OEE, as only a modest decrease in cell respiration could be sufficient to fully alleviate hypoxia. Several drugs have been tested preclinically for this aim, including targeting pathways upstream of OXPHOS (<italic>e.g</italic>., glycolysis with 2-deoxyglucose and the oxidative pathway of lactate with monocarboxylate transporter inhibitors) or the electron transport chain (ETC) either directly or indirectly (<italic>e.g</italic>., Rotenone, Antimycin A, Oligomycin, Metformin, Arsenic trioxide and Insulin) [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Intriguingly, examples exist of drugs inhibiting cancer cell respiration in vitro but devoid of any radiosensitizing effects in vivo, with Mito-metformin10 and statins as typical examples [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. This type of observations emphasizes that in vivo experimentation is mandatory to confirm the radiosensitization properties of each candidate drug.</p><p id="Par5">Over the past 10 years, we have studied mitochondria-targeted antioxidants for their capability to prevent mouse melanoma, human breast cancer and human pancreatic cancer metastasis [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>]. This family of drugs comprise MitoTEMPO, MitoQ and SKQ1 [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>], among which MitoQ singles out as it has already successfully passed Phase I safety clinical trials [<xref ref-type="bibr" rid="CR20">20</xref>]. Molecularly, MitoTEMPO, MitoQ and SKQ1 all comprise a positively charged hydrophobic triphenylphosphonium (TPP<sup>+</sup>) group, a linker, and an antioxidant moiety (ubiquinone in the case of MitoQ) [<xref ref-type="bibr" rid="CR23">23</xref>]. Previous research demonstrated that the TPP<sup>+</sup> group allows transmembrane passage and ensures mitochondrial accumulation driven by the mitochondrial potential [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Hence, MitoQ is primarily found adsorbed to the inner mitochondrial membrane, where its reduced form (ubiquinol) acts as an antioxidant, becoming oxidized to ubiquinone, which is then reduced by ETC Complex II back to ubiquinol, thus restoring its antioxidant potential [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. In the cancer cell models that we previously tested, MitoQ inhibited electron leak from the ETC, mitochondrial ROS (mtROS) production, and, consequently, mtROS signaling [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>]. In this context, we recently showed that MitoQ can inhibit human breast cancer cells migration induced by subclinical doses of photon irradiation [<xref ref-type="bibr" rid="CR28">28</xref>]. However, whether MitoQ and/or other mitochondria-targeted antioxidants alter tumor radiosensitivity is unknown.</p><p id="Par6">Here, we report that MitoQ dose-dependently inhibits cancer cell respiration, with full inhibition reached at nanomolar doses in several different human cancer cell lines. MitoTEMPO and SKQ1 were devoid of such effects. We further demonstrate that MitoQ can radiosensitize human breast tumors in mice at least partially through the OEE. It did so at a dose of 18&#x02009;mg/kg <italic>per os</italic> previously reported to be clinically relevant [<xref ref-type="bibr" rid="CR29">29</xref>].</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>MitoQ reduces the oxygen consumption rate of human cancer cells</title><p id="Par7">To test whether MitoQ could radiosensitize cancer cells, we selected two human breast cancer (BC) cell lines representing different metabolic phenotypes as main models, with MCF7 known to be more oxidative than MDA-MB-231 cells in vitro [<xref ref-type="bibr" rid="CR30">30</xref>]. MitoQ was tested at doses ranging from 62.5&#x02009;nM to 1&#x02009;&#x000b5;M, <italic>i.e</italic>., doses that can be achieved in human plasma and tissues [<xref ref-type="bibr" rid="CR29">29</xref>], with a readout time of 24&#x02009;h post-treatment. In 2D culture, MitoQ dose-dependently inhibited the mitochondrial oxygen consumption rate (mtOCR) of both cell lines, similarly affecting basal mtOCR, maximal mtOCR and mtOCR linked to ATP production (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). While the smallest tested dose of MitoQ (62.5&#x02009;nM) already significantly inhibited mitochondrial respiration, full inhibition down to a mtOCR statistically not different from 0 was achieved at doses of 500&#x02009;nM and 250&#x02009;nM for MCF7 (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>) and MDA-MB-231 (Fig. <xref rid="Fig1" ref-type="fig">1b</xref>) cells, respectively.<fig id="Fig1"><label>Fig. 1</label><caption><title>MitoQ dose-dependently reduces human breast cancer cell oxygen consumption rate.</title><p><bold>a,</bold>
<bold>b</bold> Human breast cancer cells were treated with increasing doses of MitoQ for 24&#x02009;h. <bold>a</bold> The oxygen consumption rate (OCR) of 5000 MCF7 cells was measured using Seahorse oximetry. The left graph represents total OCR measurements over time with the sequential addition of Oligomycin, FCCP, and Rotenone (Rot) together with Antimycin A (AA). From Seahorse traces, basal, maximal and ATP-linked mitochondrial OCRs (mtOCRs) were calculated (<italic>n</italic>&#x02009;=&#x02009;4). Full mtOCR inhibition was reached at 500&#x02009;nM MitoQ (arrow). <bold>b</bold> Same as in <bold>a</bold>, but assessing 10 000 MDA-MB-231 cells. Full mtOCR inhibition was reached at 250&#x02009;nM MitoQ (arrow). All data are shown as means&#x02009;&#x000b1;&#x02009;SEM. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.005 by one-way ANOVA with Dunnett&#x02019;s multiple comparisons test.</p></caption><graphic xlink:href="41420_2024_2277_Fig1_HTML" id="d33e491"/></fig></p><p id="Par8">Based on this observation, we wondered whether other mitochondria-targeted antioxidants could inhibit BC cell respiration. We tested lead compounds MitoTEMPO, whose antioxidant moiety is superoxide dismutase mimetic piperidine nitroxide (TEMPO), and SKQ1, possessing a plastoquinone antioxidant group [<xref ref-type="bibr" rid="CR22">22</xref>]. Surprisingly, neither MitoTEMPO (Figure <xref rid="MOESM1" ref-type="media">S1a</xref>) nor SKQ1 (Figure <xref rid="MOESM1" ref-type="media">S1b</xref>) significantly impacted MCF7 and MDA-MB-231 basal mtOCR, maximal mtOCR or mtOCR linked to ATP production. Thus, among tested mitochondria-targeted antioxidants, only MitoQ was able to induce metabolic oxygen sparing. We therefore reasoned that MitoQ could potentially produce an OEE at clinically relevant doses in the context of radiotherapy.</p><p id="Par9">To broaden the scope, we tested additional human cancer cell lines of other origins. MitoQ was capable of inhibiting basal mtOCR, maximal mtOCR and mtOCR linked to ATP production in SiHa human cervix cancer (Fig. <xref rid="Fig2" ref-type="fig">2a</xref>), PC3 human prostate cancer (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>) and HCT116 human colon cancer (Fig. <xref rid="Fig2" ref-type="fig">2c</xref>) cells. Full mtOCR inhibition was reached at a MitoQ concentration of 250&#x02009;nM in both PC3 and HCT116 cell lines. SiHa cells, which are known to be highly oxidative [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>], were comparatively less sensitive, with a&#x02009;~&#x02009;60% inhibition of basal mtOCR reached at 1&#x02009;&#x000b5;M (Fig. <xref rid="Fig2" ref-type="fig">2a</xref>). Overall, all tested human cancer cell lines responded to MitoQ with a decreased mtOCR.<fig id="Fig2"><label>Fig. 2</label><caption><title>MitoQ dose-dependently reduces the oxygen consumption rate of other human cancer cells.</title><p><bold>a</bold>&#x02013;<bold>c</bold> Cancer cells were treated with increasing doses of MitoQ for 24&#x02009;h, and the oxygen consumption rate (OCR) of 10 000 cells/well was measured using Seahorse oximetry. Left graphs represent total OCR measurements over time. From Seahorse traces, basal, maximal and ATP-linked mitochondrial OCRs (mtOCRs) were calculated and are displayed on the right. <bold>a</bold> SiHa human cervix cancer cells were tested (<italic>n</italic>&#x02009;=&#x02009;4). <bold>b</bold> PC3 human prostate cancer cells were tested (<italic>n</italic>&#x02009;=&#x02009;4). Full mtOCR inhibition was reached at 250&#x02009;nM MitoQ (arrow). <bold>c</bold> HCT116 human prostate cancer cells were tested (<italic>n</italic>&#x02009;=&#x02009;4). Full mtOCR inhibition was reached at 250&#x02009;nM MitoQ (arrow). All data are shown as means&#x02009;&#x000b1;&#x02009;SEM. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.005 by one-way ANOVA with Dunnett&#x02019;s multiple comparisons test.</p></caption><graphic xlink:href="41420_2024_2277_Fig2_HTML" id="d33e565"/></fig></p></sec><sec id="Sec4"><title>MitoQ induces a glycolytic switch in human breast cancer cells</title><p id="Par10">In MCF7 cells, OXPHOS inhibition by 500&#x02009;nM MitoQ decreased mitochondrial ATP production to the same extent as a treatment with 0.5&#x02009;&#x000b5;M Rotenone + 0.5&#x02009;&#x000b5;M Antimycin A, but the effects were not additive (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>). Mitochondrial potential (&#x00394;&#x003a8;) was nevertheless dose-dependently increased (Fig. <xref rid="Fig3" ref-type="fig">3b</xref>), reflecting the accumulation of positively charged MitoQ at the inner mitochondrial membrane [<xref ref-type="bibr" rid="CR33">33</xref>]. Upon OXPHOS inhibition, the initially highly oxidative MCF7 cells switched to a more glycolytic metabolism characterized by enhanced glucose uptake and lactate release (Fig. <xref rid="Fig3" ref-type="fig">3c</xref>) with increased cytosolic ATP production (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>). Like MCF7, MDA-MB-231 cells treated with 250&#x02009;nM MitoQ had reduced mitochondrial ATP production (Fig. <xref rid="Fig3" ref-type="fig">3d</xref>) despite increased &#x00394;&#x003a8; (Fig. <xref rid="Fig3" ref-type="fig">3e</xref>). These cells also had increased glucose uptake and lactate release (Fig. <xref rid="Fig3" ref-type="fig">3f</xref>), but this effect was not sufficient to prevent a drop in cytosolic ATP levels (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><title>MitoQ induces a glycolytic switch in human breast cancer cells.</title><p><bold>a</bold> MCF7 breast cancer cells were treated &#x000b1; 500&#x02009;nM MitoQ for 24&#x02009;h and subjected to subcellular fractionation. Mitochondrial and cytosolic ATP were measured using a fluorescence assay and are reported in the left and right graphs, respectively (<italic>n</italic>&#x02009;=&#x02009;3). <bold>b</bold> MCF7 cells were treated with increasing doses of MitoQ for 24&#x02009;h, and &#x00394;&#x003a8; was measured <italic>via</italic> JC-10 fluorescence (<italic>n</italic>&#x02009;=&#x02009;6). <bold>c</bold> Glucose consumption and lactate production rates were measured in MCF7 cells pretreated for 24&#x02009;h&#x02009;&#x000b1;&#x02009;500&#x02009;nM MitoQ (<italic>n</italic>&#x02009;=&#x02009;6). <bold>d</bold> As in (a) but using MDA-MB-231 cancer cells treated &#x000b1; 250&#x02009;nM MitoQ (<italic>n</italic>&#x02009;=&#x02009;3). <bold>e</bold> As in (b) but using MDA-MB-231 cells (<italic>n</italic>&#x02009;=&#x02009;6). <bold>f</bold> As in <bold>c</bold> but using MDA-MB-231 cancer cells treated &#x000b1; 250&#x02009;nM MitoQ (<italic>n</italic>&#x02009;=&#x02009;6). <bold>g</bold> Seahorse XF cell energy map of cancer cells plotted by their basal OCR and basal extracellular acidification rate (ECAR) before and 24&#x02009;h after treatment with MitoQ at the concentrations identified to bring ATP production linked to mtOCR to 0 (SiHa, 1&#x02009;&#x000b5;M; MCF7, 500&#x02009;nM; MDA-MB-231, 250&#x02009;nM; PC3, 250&#x02009;nM; HCT116, 250&#x02009;nM) (<italic>n</italic>&#x02009;=&#x02009;4&#x02013;6). All data are shown as means&#x02009;&#x000b1;&#x02009;SEM. <italic>ns</italic>
<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.005 compared to untreated controls; by one-way ANOVA with Tukey&#x02019;s multiple comparisons test (<bold>a, b, d, e</bold>) or Student&#x02019;s t test (<bold>c, f</bold>).</p></caption><graphic xlink:href="41420_2024_2277_Fig3_HTML" id="d33e674"/></fig></p><p id="Par11">To better estimate the amplitude of the glycolytic switch, we measured extracellular acidification rates (ECAR) at the precise MitoQ doses that optimally inhibited mtOCR. MitoQ decreased the OCR (Figs. <xref rid="Fig1" ref-type="fig">1</xref> and <xref rid="Fig2" ref-type="fig">2</xref>) and increased the ECAR (Fig. <xref rid="MOESM1" ref-type="media">S2</xref>) of all tested cell lines, confirming a MitoQ-induced glycolytic switch. Figure <xref rid="Fig3" ref-type="fig">3g</xref> depicts the glycolytic switch in MCF7, MDA-MB-231, SiHa, PC3 and HCT116 human cancer cells.</p><p id="Par12">Conclusively at this stage, our data showed that MitoQ dose-dependently reduces cancer cell respiration, which involves a compensatory increase in their glycolytic rate.</p></sec><sec id="Sec5"><title>MitoQ radiosensitizes hypoxic human breast cancer cell in vitro</title><p id="Par13">A potential OEE in response to MitoQ was tested by comparing cancer cells treated &#x000b1; MitoQ under normoxia (21% O<sub>2</sub>) and hypoxia (1% O<sub>2</sub>). Under normoxia, a pretreatment with MitoQ (500&#x02009;nM for 24&#x02009;h) did not impact MCF7 cell number at 3 days (Fig. <xref rid="Fig4" ref-type="fig">4a</xref>) or 7 days post-irradiation (Fig. <xref rid="Fig4" ref-type="fig">4b</xref>). Under hypoxia, MitoQ radiosensitized hypoxic MCF7 cells, which was seen 7 days post-irradiation; while hypoxia significantly increased the irradiation dose necessary to kill 10% of cells (LD<sub>10</sub>), MitoQ reduced the LD<sub>10</sub> of hypoxic MCF7 cells down to levels seen in normoxia (Fig. <xref rid="Fig4" ref-type="fig">4b</xref>). However, this was not sufficient to reduce clonogenic survival after hypoxia (Fig. <xref rid="Fig4" ref-type="fig">4c</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><title>MitoQ radiosensitizes hypoxic human breast cancer cell in vitro.</title><p><bold>a</bold> MCF7 human breast cancer cells were treated &#x000b1; 500&#x02009;nM MitoQ for 24&#x02009;h under normoxia (21% O<sub>2</sub>) or hypoxia (1% O<sub>2</sub>). On the next day, cells were irradiated with increasing doses. Cells were then maintained under normoxia or hypoxia until surviving fractions were determined (<bold>a</bold>) 3 days (<italic>n</italic>&#x02009;=&#x02009;5) or (<bold>b</bold>) 7 days post irradiation. LD<sub>10</sub> for day 7 are displayed in the graph on the right (<italic>n</italic>&#x02009;=&#x02009;5). <bold>c</bold> MCF7 cells were pretreated &#x000b1; 500&#x02009;nM MitoQ for 24&#x02009;h, irradiated with increasing doses, and tested for clonogenicity. The graph shows the surviving fraction as a function of the irradiation dose (<italic>n</italic>&#x02009;=&#x02009;3). <bold>d</bold> As in <bold>a</bold> but using MDA-MB-231 human breast cancer cells treated &#x000b1; 250&#x02009;nM MitoQ (<italic>n</italic>&#x02009;=&#x02009;6). <bold>e</bold> As in <bold>b</bold> but using MDA-MB-231 cells treated &#x000b1; 250&#x02009;nM MitoQ (<italic>n</italic>&#x02009;=&#x02009;5-6). <bold>f</bold> As in <bold>c</bold> but using MDA-MB-231 cells treated &#x000b1; 250&#x02009;nM MitoQ (<italic>n</italic>&#x02009;=&#x02009;3). All data are shown as means&#x02009;&#x000b1;&#x02009;SEM. <italic>ns</italic> P&#x02009;&#x0003e;&#x02009;0.05, **P&#x02009;&#x0003c;&#x02009;0.01 compared to the normoxic control; <sup>#</sup>P&#x02009;&#x0003c;&#x02009;0.05, <sup>###</sup>P&#x02009;&#x0003c;&#x02009;0<sup>.</sup>001 compared to hypoxia alone; by one-way ANOVA with Tukey&#x02019;s multiple comparisons test (<bold>b, d</bold>) or Student&#x02019;s t test (<bold>e</bold>).</p></caption><graphic xlink:href="41420_2024_2277_Fig4_HTML" id="d33e796"/></fig></p><p id="Par14">Similarly to MCF7 cells, MitoQ (250&#x02009;nM for 24&#x02009;h) did not alter the radiosensitivity of normoxic MDA-MB-231 cells (Fig. <xref rid="Fig4" ref-type="fig">4d</xref>). However, it radiosensitized hypoxic MDA-MB-231 cells, which was seen both by analyzing cell number 7 days post-irradiation (Fig. <xref rid="Fig4" ref-type="fig">4e</xref>) and by clonogenic survival (Fig. <xref rid="Fig4" ref-type="fig">4f</xref>). We therefore concluded that MitoQ can radiosensitize MDA-MB-231, but not MCF7 cancer cells, possibly through the OEE, which we next tested in 3D.</p></sec><sec id="Sec6"><title>MitoQ decreases hypoxia in human breast cancer spheroids</title><p id="Par15">Spheroids are known to have an inner hypoxic core resulting from the respiration of outer cell layers. To test reoxygenation by MitoQ, we used a hypoxia-inducible factor (HIF)-binding sites-thymidine kinase (TK) promoter-fluorescent enhanced yellow fluorescent protein (eYFP) construct (HIF-TK-eYFP) reporting on the activity of hypoxia-inducible factors HIF-1 and HIF-2 [<xref ref-type="bibr" rid="CR34">34</xref>]. MitoQ at the aforementioned concentrations produced no change in spheroid size after 24&#x02009;h of treatment (Fig. <xref rid="Fig5" ref-type="fig">5</xref>a, <xref rid="Fig5" ref-type="fig">b</xref>), but significantly decreased MDA-MB-231 HIF-TK-eYFP fluorescence by ~30%, while in MCF7 there was no change (Fig. <xref rid="Fig5" ref-type="fig">5</xref>a, <xref rid="Fig5" ref-type="fig">c</xref>). Of note, basal differences in eYFP signal intensity between the two types of spheroids can be attributed to the fact that MDA-MB-231 cells form tight spheroids with a true hypoxic core, whereas MCF7 cells form homogenously loose clusters of cells as spheroids, more permeable to oxygen [<xref ref-type="bibr" rid="CR35">35</xref>]. Although our results suggested that MitoQ can reoxygenate glycolytic tumor spheroids, at this stage they remained inconclusive with regard to hypoxia because HIF activity not only depends on microenvironmental pO<sub>2</sub> but also on confounding factors, including redox state [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>] and intracellular pyruvate levels [<xref ref-type="bibr" rid="CR38">38</xref>].<fig id="Fig5"><label>Fig. 5</label><caption><title>MitoQ increases MDA-MB-231 spheroid oxygenation.</title><p><bold>a&#x02013;c</bold> HIF-TK-eYFP spheroids were treated &#x000b1; MitoQ for 24&#x02009;h (500&#x02009;nM for MCF7 and 250&#x02009;nM for MDA-MB-231 cells). <bold>a</bold> Representative microscopy images of MCF7 and MDA-MB-231 spheroids after treatment, where the eYFP signal appears in green (scale bar = 100&#x02009;&#x000b5;m). A color bar is provided. <bold>b</bold> MCF7 (left graph, <italic>n</italic>&#x02009;=&#x02009;7-8) and MDA-MB-231 (right graph, <italic>n</italic>&#x02009;=&#x02009;8) spheroid size. <bold>c</bold> Quantification of MCF7 (left graph, <italic>n</italic>&#x02009;=&#x02009;7-8) and MDA-MB-231 (right graph, <italic>n</italic>&#x02009;=&#x02009;8) eYFP expression reporting on HIF activity. All data are shown as means&#x02009;&#x000b1;&#x02009;SEM. <italic>ns</italic> P&#x02009;&#x0003e;&#x02009;0.05, **P&#x02009;&#x0003c;&#x02009;0.01, by Student&#x02019;s t test <bold>(b, c)</bold>.</p></caption><graphic xlink:href="41420_2024_2277_Fig5_HTML" id="d33e880"/></fig></p></sec><sec id="Sec7"><title>MitoQ radiosensitizes MDA-MB-231 human breast tumors in mice</title><p id="Par16">We finally aimed to test whether MitoQ could radiosensitize orthotopic human breast tumors in mice. For MCF7, electron paramagnetic resonance (EPR) oximetry revealed a basal tumor oxygenation above 10 mm-Hg, which a single clinically relevant dose of MitoQ (18&#x02009;mg/kg <italic>per os</italic>) did not increase (Fig. <xref rid="Fig6" ref-type="fig">6a</xref>). In line with this observation, MitoQ did not radiosensitize MCF7 tumors in mice (Fig. <xref rid="Fig6" ref-type="fig">6b</xref>). In MDA-MB-231 tumors in mice, EPR was not sensitive enough to detect a significant increase in pO<sub>2</sub> after a single dose of MitoQ (Fig. <xref rid="Fig6" ref-type="fig">6c</xref>). To better detect hypoxia, we therefore used immunohistochemistry with pimonidazole, which revealed a significant decrease in MDA-MB-231 tumor hypoxia 24&#x02009;h after MitoQ administration (Fig. <xref rid="Fig6" ref-type="fig">6d</xref>). Of note, a statistical outlier was excluded from the MitoQ group. Tumor reoxygenation was associated with effective tumor radiosensitization using a single dose of radiotherapy (5&#x02009;Gy), with measured tumor doubling times of 14.9&#x02009;&#x000b1;&#x02009;1.5 days in vehicle-treated mice, 20.1&#x02009;&#x000b1;&#x02009;1.0 days for MitoQ alone (+ 5.2 days, P&#x02009;&#x0003e;&#x02009;0.05), 23.7&#x02009;&#x000b1;&#x02009;1.8 days with a single dose irradiation of 5&#x02009;Gy (+ 8.8 days, P&#x02009;&#x0003e;&#x02009;0.05), and 36.3&#x02009;&#x000b1;&#x02009;5.8 days for the combination treatment (+ 21.4 days, P&#x02009;&#x0003c;&#x02009;0.005) (Fig. <xref rid="Fig6" ref-type="fig">6e</xref>). Of note, a statistical outlier was excluded from the 5&#x02009;Gy group and another from the combination group.<fig id="Fig6"><label>Fig. 6</label><caption><title>MitoQ radiosensitizes human breast tumors in mice.</title><p><bold>a&#x02013;f</bold> Human breast cancer cells were implanted orthotopically in the breast of immunodeficient mice. When average tumor volumes reached 100 mm<sup>3</sup> (Day -1), mice were randomly assigned to a treatment group. <bold>a</bold> On Day -1, MCF7-bearing mice received MitoQ (18&#x02009;mg/kg <italic>per os</italic>) or saline. MCF7 tumor pO<sub>2</sub> was measured using electron paramagnetic resonance (EPR) after treatment on Day 0 (<italic>n</italic>&#x02009;=&#x02009;7&#x02013;8). <bold>b</bold> On Day -1, MCF7-bearing mice received MitoQ (18&#x02009;mg/kg <italic>per os</italic>) or saline. On Day 0, a local 5&#x02009;Gy or a sham irradiation was delivered to mice. The graph shows tumor growth over time with the dashed line representing tumor volume doubling (<italic>n</italic>&#x02009;=&#x02009;3). <bold>c</bold> As in <bold>a</bold> but using MDA-MB-231 tumors in mice (<italic>n</italic>&#x02009;=&#x02009;8&#x02013;9). <bold>d</bold> On Day -1, MDA-MB-231-bearing mice received MitoQ (18&#x02009;mg/kg <italic>per os</italic>) or not. On Day 0, all mice received an intraperitoneal injection of pimonidazole (60&#x02009;mg/kg) and were sacrificed 90&#x02009;min later. Representative pictures are shown on the left, where pimonidazole staining indicating hypoxia appears in brown. Pimonidazole-positive area normalized for total tumor area is shown in the right graph, where each dot represents a mouse tumor (<italic>n</italic>&#x02009;=&#x02009;9&#x02013;12, scale bars = 500&#x02009;&#x000b5;m). <bold>e</bold> As in <bold>b</bold>, but using MDA-MB-231 tumors in mice. The graph on the left shows tumor growth over time. Tumor doubling times are shown on the right graph (<italic>n</italic>&#x02009;=&#x02009;7-8 per group). <bold>f</bold> MDA-MB-231 tumor-bearing mice received MitoQ (18&#x02009;mg/kg <italic>per os</italic>) for 5 consecutive days (from Day -1 to Day +3; 5 doses in total) or not. Radiotherapy or sham irradiation was delivered 24&#x02009;h after each dose of MitoQ, i.e., from Day 0 to Day +4 (5 &#x000d7; 2&#x02009;Gy). The graph shows tumor growth over time (<italic>n</italic>&#x02009;=&#x02009;8&#x02013;9 per group) with the dashed line representing tumor doubling. All data are shown as means&#x02009;&#x000b1;&#x02009;SEM. <italic>ns</italic>
<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05, *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 by Student&#x02019;s t test (<bold>a, c, d</bold>). <italic>ns</italic> P&#x02009;&#x0003e;&#x02009;0.05, ***P&#x02009;&#x0003c;&#x02009;0.005 compared to 0&#x02009;Gy; <sup>##</sup>P&#x02009;&#x0003e;&#x02009;0.01 compared to MitoQ without irradiation; <sup>$</sup>P&#x02009;&#x0003c;&#x02009;0.05 compared to irradiation without MitoQ; by one<sup>-</sup>way ANOVA with Tukey&#x02019;s multiple comparisons test (<bold>e</bold>) ; *&#x02009;P &#x0003c;&#x02009;0.05, **P&#x02009;&#x0003c;&#x02009;0.01, ***P&#x02009;&#x0003c;&#x02009;0.001 by two-way ANOVA (<bold>f</bold>).</p></caption><graphic xlink:href="41420_2024_2277_Fig6_HTML" id="d33e1006"/></fig></p><p id="Par17">This prompted us to test a fractionated radiotherapy regimen. MDA-MB-231 tumor-bearing mice were locally irradiated with a daily dose of 2&#x02009;Gy for 5 consecutive days, with or without MitoQ administration as a pretreatment prior to each irradiation. Measurements of tumor growth revealed that the combination treatment was more effective than individual treatments (Fig. <xref rid="Fig6" ref-type="fig">6f</xref>). One hundred days after treatment, tumor doubling times were not reached in mice treated with 5 x MitoQ + 5 &#x000d7; 2&#x02009;Gy, while mean doubling times were 11.5&#x02009;&#x000b1;&#x02009;0.6 days in the control group, 19.4&#x02009;&#x000b1;&#x02009;3.3 days in the 5 x MitoQ group (P&#x02009;&#x0003e;&#x02009;0.05 compared to control), and 52.4&#x02009;&#x000b1;&#x02009;6.8 days in the 5 &#x000d7; 2&#x02009;Gy group (P&#x02009;&#x0003c;&#x02009;0.01 compared to control). Of note, one mouse was excluded in the 5 &#x000d7; 2&#x02009;Gy group due to an ascites unrelated to the experiment. Whole curve analyses confirmed that the combination treatment was significantly more effective that MitoQ alone (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) or fractionated radiotherapy alone (P&#x02009;&#x0003c;&#x02009;0.01). Interestingly, chronic MitoQ administration for 5 days modestly but significantly (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05) delayed tumor growth in the absence of irradiation. Furthermore, vimentin staining of the tumors that never reached the doubling endpoint in the combination group revealed the presence of remaining cancer cells (Figure <xref rid="MOESM1" ref-type="media">S3</xref>), indicating that longer treatments times would be required to potentially eradicate orthotopic MDA-MB-231 tumors in mice.</p></sec></sec><sec id="Sec8" sec-type="discussion"><title>Discussion</title><p id="Par18">We report that MitoQ radiosensitizes tumors at least partially through the OEE, as it radiosensitized hypoxic but not normoxic cancer cells and reduced tumor hypoxia in vivo.</p><p id="Par19">In this study, we observed that MitoQ dose-dependently inhibited the respiration of different types of human cancer cells. This was unexpected because the reported mode of action of MitoQ is classically that of an antioxidant selectively inactivating mtROS [<xref ref-type="bibr" rid="CR39">39</xref>]. Our data suggest another mode of action through which MitoQ, inserted into the inner mitochondrial membrane [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR40">40</xref>], blocks electron flux through the ETC, resulting in O<sub>2</sub> sparing. Similarly to Coenzyme Q10, MitoQ can accept electrons from Complexes I and II [<xref ref-type="bibr" rid="CR29">29</xref>]. However, due to steric hindrance of the TPP<sup>+</sup> group [<xref ref-type="bibr" rid="CR27">27</xref>], MitoQ would not be able to transfer these electrons to Complex III and thus block electron flux through the ETC [<xref ref-type="bibr" rid="CR27">27</xref>]. Of note, we verified that MitoQ did not replace O<sub>2</sub> as a final electron acceptor at Complex IV, which was evidenced by showing that increasing doses of MitoQ did not generate increasing levels of mitochondrial ATP. MitoQ at nanomolar doses (250 - 500&#x02009;nM) rather decreased mitochondrial ATP generation in human BC cells to the same extent as Rotenone + Antimycin A. Cells compensated by increasing glycolytic ATP production, which could explain why MitoQ exerts cytostatic but not cytotoxic effects on human BC cells [<xref ref-type="bibr" rid="CR18">18</xref>] as well as the modest growth delay observed upon chronic mouse treatment with MitoQ alone.</p><p id="Par20">Among tested mitochondria-targeted antioxidants, only MitoQ dose-dependently decreased cancer cell respiration, whereas MitoTEMPO and SKQ1 had modest effects that were not dose-dependent. This observation rules out a class effect, which could be explained by different localizations of the mitochondria-targeted antioxidants with respect to the inner mitochondrial membrane and ETC complexes as well as different antioxidant capacities and turnover rates on target. To our knowledge, redox recycling involving Complex II has been reported for MitoQ [<xref ref-type="bibr" rid="CR27">27</xref>], but not for other mitochondria-targeted antioxidants. This would support the dose-dependent inhibition of cell respiration that we observed, as a single molecule of MitoQ could sequentially and repeatedly capture electrons that would be transferred to electron acceptors other than O<sub>2</sub>. The paradoxical effect of MitoQ on &#x00394;&#x003a8; (a decrease was expected but an increase was observed) has been reported by others: MitoQ creates a pseudo-mitochondrial membrane potential as the positively charged molecule (TPP<sup>+</sup> group) accumulates at the inner mitochondrial membrane [<xref ref-type="bibr" rid="CR40">40</xref>].</p><p id="Par21">According to mathematical models [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>], the most adequate mode for tumor reoxygenation is by inhibiting cancer cell respiration rather than increasing vascular O<sub>2</sub> delivery. However, not all drugs that inhibit cancer cell respiration in vitro can radiosensitize tumors [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR15">15</xref>], which could be linked to issues involving drug delivery, biodistribution, stability in biological systems, metabolism, clearance, and/or on- and off-target effects impacting the radiotherapeutic response. Thus, associating a reduced mtOCR in vitro to in vivo tumor radiosensitization is not straightforward. Here, we observed that MitoQ can radiosensitize tumors in vivo when using single-dose radiotherapy and more clinically relevant fractionated mode radiotherapy. Radiosensitization was seen when the tumors were hypoxic (MDA-MB-231 model) but not when they had basal oxygen levels above 10 mm-Hg (MCF7 model), further supporting that MitoQ acts, at least in part, through the OEE. The inability of glycolytic MDA-MB-231 cancer cells to rescue global ATP production through further increasing the glycolytic rate, while MCF7 cells succeeded, may further contribute to radiosensitization, as energy is necessary for repair. We did not test MitoTEMPO nor SKQ1 in vivo, as these drugs minimally influenced cancer cell respiration in vitro.</p><p id="Par22">In vitro, maximal OCR inhibition 24&#x02009;h after a single dose of MitoQ was reached at doses ranging from 250&#x02009;nM to 1&#x02009;&#x000b5;M. This range is close to the MitoQ concentrations measured in vivo after bolus delivery. In mice, we previously reported that free MitoQ reached a plasma concentration of ~50&#x02009;nM 4&#x02009;h after the administration of 12&#x02009;mg/kg to 24&#x02009;mg/kg <italic>per os</italic> [<xref ref-type="bibr" rid="CR18">18</xref>]. A similar ~50&#x02009;nM concentration was achieved in human plasma 1&#x02009;h after a dose of 1&#x02009;mg/kg MitoQ <italic>per os</italic> [<xref ref-type="bibr" rid="CR29">29</xref>]. In mouse tissues, MitoQ concentrations reached ~100 nmol/kg in the lungs, between ~50 and ~100 nmol/kg in the heart, and between ~400 nmol/kg and ~1.2 &#x000b5;mol/kg in the liver and kidneys. Since MitoQ accumulates in mitochondria and because several doses should be delivered in the context of fractionated radiotherapy, we believe that our observations are clinically relevant.</p><p id="Par23">Although there is previous in vitro evidence that MitoQ could display cancer cell selectivity (which has been purported to be based on higher mitochondrial membrane potential in cancer compared to nonmalignant cells) [<xref ref-type="bibr" rid="CR18">18</xref>], selectivity is not needed in the context of radiotherapy because normal tissues already have a pO<sub>2</sub> above 10-mm Hg and therefore cannot be further radiosensitized through the OEE. Rather, several groups previously showed that MitoQ acts as a radioprotective agent for normal tissues, including cultured human astrocytes [<xref ref-type="bibr" rid="CR41">41</xref>], mouse intestines [<xref ref-type="bibr" rid="CR42">42</xref>], and rat testis [<xref ref-type="bibr" rid="CR43">43</xref>]. In rat testis, MitoQ promoted mitochondrial ATP production [<xref ref-type="bibr" rid="CR43">43</xref>], whereas it reduced ATP production by cancer cells (our study). In mouse intestines, MitoQ inhibited mitochondria-dependent apoptosis and inflammation [<xref ref-type="bibr" rid="CR42">42</xref>]. Whether these differences between normal and tumor tissues are driven by the lower mitochondrial potential of nonmalignant cells compared to metabolically hyperactive cancer cells warrants further investigation.</p><p id="Par24">Although we report that MitoQ can radiosensitize breast tumors <italic>via</italic> the OEE, additional mechanisms are possible. Autophagy, which is well-known to modulate radiosensitivity [<xref ref-type="bibr" rid="CR44">44</xref>], is one among them. Previous studies in nonmalignant cells have indeed reported that MitoQ can stimulate autophagy, either through caspase-1 activation following thioredoxin-interacting protein binding to NOD-like receptor family pyrin domain containing 3 [<xref ref-type="bibr" rid="CR45">45</xref>] or by an AMP-activated protein kinase-regulated mechanism [<xref ref-type="bibr" rid="CR41">41</xref>]. Likewise, in the context of osteoarthritis it was found that MitoQ activates a nuclear factor erythroid 2-related factor 2-Parkin-regulated mitophagy program in chondrocytes [<xref ref-type="bibr" rid="CR46">46</xref>]. Interestingly, MitoQ-induced autophagy was proposed to originate from the creation of a pseudo-mitochondrial membrane potential when the positively charged drug accumulates within mitochondria [<xref ref-type="bibr" rid="CR40">40</xref>]. To our knowledge, whether MitoQ also triggers autophagy to radiosensitize tumors is unknown.</p><p id="Par25">Conclusively, our study shows that MitoQ is a tumor radiosensitizer, acting at least partially though the OEE. This is not a class effect, as the other mitochondria-targeted antioxidants that we tested did not inhibit OXPHOS in cancer cells.</p></sec><sec id="Sec9" sec-type="materials|methods"><title>Materials and Methods</title><sec id="Sec10"><title>Ethical statement</title><p id="Par26">All mouse experiments were performed with the approval of UCLouvain <italic>Comit&#x000e9; d&#x02019;Ethique pour l&#x02019;Exp&#x000e9;rimentation Animale</italic> (approval ID: 2020/UCL/MD/033) according to national and European animal care regulations.</p></sec><sec id="Sec11"><title>Cells and cell culture</title><p id="Par27">MCF7 (American Type Culture Collection [ATCC], Manassas, VA, USA; catalog #HTB-22) and MDA-MB-231 (ATCC, catalogue #HTB-26) human breast adenocarcinoma cancer cells, SiHa human cervix cancer cells (ATCC, catalog #HTB-35), PC3 human prostate cancer cells (ATCC, catalog #CRL-1435) and HCT116 human colon cancer cells (ATCC, catalog #CCL-247) were cultured at 37&#x02009;&#x000b0;C in a 5% CO<sub>2</sub> humidity-controled incubator in DMEM containing GlutaMAX, 4.5&#x02009;g/L <italic>D</italic>-glucose without pyruvate (ThermoFisher Scientific, Dilbeek, Belgium; catalogue #10566016), supplemented with 10% FBS (Sigma-Aldrich, Overijse, Belgium). Cell authenticities were routinely verified with short tandem repeat testing (Eurofins Genomics, Ebersberg, Germany). Cultured cells were routinely checked for mycoplasma contamination (MycoAlert Plus, Lonza, Verviers, Belgium; catalog #LT07-710).</p></sec><sec id="Sec12"><title>Cells, cell treatments and numbering</title><p id="Par28">Where indicated, cells were treated with Mitoquinol mesylate (MitoQ) [<xref ref-type="bibr" rid="CR47">47</xref>], (2-(2,2,6,6-tetramethylpiperidin-1-oxyl-4-ylamino)-2-oxoethyl)triphenylphosphonium chloride (MitoTEMPO; Sigma-Aldrich catalog #SML0737) or Visomitin (SKQ1; MedChemExpress, Sollentuna, Sweden; catalog #HY-100474). Hypoxia (1% O<sub>2</sub>) was achieved by a 24&#x02009;h incubation in a Whitley H35 hypoxystation (Don Whitley Scientific, Bingley, UK). Subconfluent cells were irradiated at a dose rate of 0.8&#x02009;Gy/min using an IBL-637 <sup>137</sup>Cs &#x003b3;-ray irradiator (Gamma Service Medical, Leipzig, Germany), and spheroids at a dose rate of 2.132&#x02009;Gy/min using a RS-2000 225&#x02009;kV irradiator (Rad Source Technologies, Buford, GA, USA). Cell numbers were determined on a SpectraMax i3x spectrophotometer equipped with a MiniMax imaging cytometer (Molecular Devices, San Jose, CA, USA).</p></sec><sec id="Sec13"><title>Metabolic assays</title><p id="Par29">Cellular OCRs and ECARs were determined on a Seahorse XFe96 bioenergetic analyzer, glucose and lactate levels in cell supernatant using enzymatic assays on an ISCUS<sup>flex</sup> CMA600 bioenergetic analyzer (Aurora Borealis Control, Schoonebeek, The Netherlands) [<xref ref-type="bibr" rid="CR31">31</xref>], mitochondrial and cytosolic ATP measurements using a CellTiter-Glo 2.0 Cell Viability Assay (Promega, Leiden, The Netherlands; catalog #G9243) after subcellular fractionation, and &#x00394;&#x003a8; using a JC-10 Mitochondrial Membrane Potential Assay Kit (Abcam, Cambridge, UK; catalogue #ab112134). Details of the procedures are available in the <xref rid="MOESM1" ref-type="media">Supplementary Information</xref>.</p></sec><sec id="Sec14"><title>Clonogenic assays</title><p id="Par30">Cells were pre-treated for 24&#x02009;h &#x000b1; MitoQ, irradiated or not, and seeded in 6-well plates (1 000 cells/well). Two weeks later, they were fixed and stained for 1&#x02009;h with 0.5% crystal violet in a 10% ethanol solution. Colonies were washed with water and counted. Results are expressed as surviving fraction (SF), where SF = #colonies/plating efficiency (PE).</p></sec><sec id="Sec15"><title>Spheroids</title><p id="Par31">Cells were stably infected with an HBR-6U lentiviral vector expressing eYFP under the control of six hypoxia-responsive element (HRE) repeats (Addgene, Watertown, MA, USA; plasmid #42621) [<xref ref-type="bibr" rid="CR34">34</xref>]. After transduction, cells were cultured in hypoxic conditions (1% O<sub>2</sub>) and selected by fluorescence-activated cell sorting (FACSAriaTM III Cell Sorter, BD Bioscience), as previously reported [<xref ref-type="bibr" rid="CR48">48</xref>]. After recovery in normoxia for one week, 5000 cells/well were plated, supplemented with 15&#x02009;&#x000b5;g/ml of rat tail collagen I (ThermoFisher Scientific, catalog #A1048301) 24&#x02009;h later, and allowed to form spheroids. Spheroids were imaged on the next day before MitoQ administration, treated &#x000b1; MitoQ, and 24&#x02009;h after MitoQ administration. All images were captured on a Leica widefield Dmi8 microscope with the same settings, quantified using the FIJI ImageJ software with a custom-written script, and analyzed according to a previously described protocol [<xref ref-type="bibr" rid="CR48">48</xref>].</p></sec><sec id="Sec16"><title>In vivo experiments</title><p id="Par32">All in vivo experiments were performed on 5-week-old female Rj:NMRI-Foxn1 nu/nu mice (Janvier Labs, Le Genest-Saint-Isle, France). Orthotopic tumor implantation was performed under anesthesia (80&#x02009;mg/kg of ketamine and 8&#x02009;mg/kg of xylazine) as previously described [<xref ref-type="bibr" rid="CR17">17</xref>]. Tumor size was then monitored every two days using an electronic caliper. When average tumor volumes reached 100 mm<sup>3</sup> (Day -1), mice were randomly assigned to a treatment group. On that day, MitoQ at a dose 18&#x02009;mg/kg [<xref ref-type="bibr" rid="CR29">29</xref>] or an equal volume of saline was administered by gavage to the indicated animal subgroups. There was not blinding. Four independent series of experiments were conducted to determine tumor pO<sub>2</sub> using EPR oximetry, to quantify tumor hypoxia using pimonidazole hydrochloride (MedChemExpress catalog #HY-105129), and to evaluate the radiosensitizing potential of MitoQ in animals treated with single dose (5&#x02009;Gy) or repeated doses (5 &#x000d7; 2&#x02009;Gy) of radiotherapy at 0.8&#x02009;Gy/min using an IBL-637 <sup>137</sup>Cs &#x003b3;-ray irradiator. Details of the procedures are available in the <xref rid="MOESM1" ref-type="media">Supplementary Material</xref>. The ethical endpoint for tumor size was 1000 mm<sup>3</sup>, which was not exceeded. For a significant Cohen effect of 2.0 at the alpha threshold of 0.05 and with a power of 90%, we used minimum 6 animals per group. Animals for which tumor implantation failed and statistical outliers were excluded from analysis.</p></sec><sec id="Sec17"><title>Statistics</title><p id="Par33">All results are presented as means &#x000b1; standard error of the mean (SEM) for <italic>n</italic> independent observations. Error bars are sometimes smaller than symbols. Outliers were identified using Dixon&#x02019;s Q test for all data except for tumor growth delays for which the robust regression followed by outlier identification (ROUT) method was used with a 1% Q. All data were analyzed using GraphPad Prism 10.2.3 considering similar variance between the groups. Two-sided Student&#x02019;s <italic>t</italic> test, one-way ANOVA with Dunnett&#x02019;s or Tukey&#x02019;s post-hoc test and two-way ANOVA were used where appropriate. P&#x02009;&#x0003c;&#x02009;0.05 was considered to be statistically significant.</p></sec></sec><sec id="Sec18" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41420_2024_2277_MOESM1_ESM.docx"><caption><p>Supplementary data</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41420-024-02277-9.</p></sec><ack><title>Acknowledgements</title><p>Authors thank Prof. Michael P. Murphy (University of Cambridge, UK) for the kind gift of MitoQ, Caroline Bouzin (UCLouvain IREC 2IP Platform), Davide Brusa (UCLouvain IREC Flow Cytometry and Cell Sorting Platform), as well as Marie Bedin, Alan Provito, Emmanuel Vandenhooft and Thibaut Vazeille for excellent technical assistance.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceived and designed the experiments: JDR, TC, MP, BG, PS. Performed the experiments and analyzed the data: JDR, SL, BM, CB, JAVdV, LM, MDSM, MK, IC, TC. Validated the data: MP, BG, PS. Wrote the manuscript: JDR, CB, PS. Edited and endorsed the manuscript: JDR, SL, BM, CB, JAVdV, LM, MDSM, MK, IC, TC, MP, BG, PS. Acquired funding: MP, BG, PS. Supervised the project: PS.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by EU Horizon2020 Marie Sk&#x00142;odowska-Curie Innovative Training Networks (ITN-ETN) grant #860245 (THERADNET), the <italic>Actions de Recherche Concert&#x000e9;es</italic> program of the <italic>Communaut&#x000e9; Fran&#x000e7;aise de Belgique</italic> (ARC 21/26-118), the Belgian <italic>Fonds National de la Recherche Scientifique</italic> (F.R.S.-FNRS; grant CDR J.0177.22), and the Louvain Foundation. JD Rondeau, S Lipari, C Beckers, M Kreuzer and I Colauzzi are THERADNET early-stage researchers. B Mathieu is a F.R.S.-FNRS PhD Fellow. M Da Silva Morais is a Postdoctoral Researcher supported by a BEWARE2 Fellowship from the R&#x000e9;gion Wallonne de Belgique - Wallonie Recherche SPW (Convention #2210063). P Sonveaux is a WELBIO Investigator and a F.R.S.-FNRS Research Director.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in this article and its supplementary information file.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par34">P Sonveaux and T Capeloa are inventors of patent application WO2022/243541 A1 &#x0201c;Molecular signature for assessing the responsiveness of cancer to mitochondria-targeted antioxidants&#x0201d;. P Sonveaux and JD Rondeau are inventors of patent application EP24186067.5 &#x0201c;Mitochondrially-targeted antioxidant compound for use in radiation therapy&#x0201d;. P Sonveaux is involved in a clinical collaboration with Antipodean Pharmaceuticals Inc. for the prevention of BC metastasis. Authors declare no other conflict of interest. Antipodean Pharmaceuticals Inc. and MitoQ Inc., who own the rights on the MitoQ molecule, were not involved in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Fendt</surname><given-names>SM</given-names></name><name><surname>Frezza</surname><given-names>C</given-names></name><name><surname>Erez</surname><given-names>A</given-names></name></person-group><article-title>Targeting metabolic plasticity and flexibility dynamics for cancer therapy</article-title><source>Cancer Discov</source><year>2020</year><volume>10</volume><fpage>1797</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-20-0844</pub-id><pub-id pub-id-type="pmid">33139243</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Fendt SM, Frezza C, Erez A. Targeting metabolic plasticity and flexibility dynamics for cancer therapy. Cancer Discov. 2020;10:1797&#x02013;807.<pub-id pub-id-type="pmid">33139243</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Warburg</surname><given-names>O</given-names></name><name><surname>Wind</surname><given-names>F</given-names></name><name><surname>Negelein</surname><given-names>E</given-names></name></person-group><article-title>The metabolism of tumors in the body</article-title><source>J Gen Physiol</source><year>1927</year><volume>8</volume><fpage>519</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1085/jgp.8.6.519</pub-id><pub-id pub-id-type="pmid">19872213</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519&#x02013;30.<pub-id pub-id-type="pmid">19872213</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Vander Heiden</surname><given-names>MG</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><article-title>Understanding the Warburg effect: The metabolic requirements of cell proliferation</article-title><source>Science</source><year>2009</year><volume>324</volume><fpage>1029</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1126/science.1160809</pub-id><pub-id pub-id-type="pmid">19460998</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 2009;324:1029&#x02013;33.<pub-id pub-id-type="pmid">19460998</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Moeller</surname><given-names>BJ</given-names></name><name><surname>Richardson</surname><given-names>RA</given-names></name><name><surname>Dewhirst</surname><given-names>MW</given-names></name></person-group><article-title>Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment</article-title><source>Cancer Metastasis Rev</source><year>2007</year><volume>26</volume><fpage>241</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s10555-007-9056-0</pub-id><pub-id pub-id-type="pmid">17440683</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Moeller BJ, Richardson RA, Dewhirst MW. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 2007;26:241&#x02013;8.<pub-id pub-id-type="pmid">17440683</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>LH</given-names></name><name><surname>Conger</surname><given-names>AD</given-names></name><name><surname>Ebert</surname><given-names>M</given-names></name><name><surname>Hornsey</surname><given-names>S</given-names></name><name><surname>Scott</surname><given-names>OC</given-names></name></person-group><article-title>The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy</article-title><source>Br J Radiol</source><year>1953</year><volume>26</volume><fpage>638</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1259/0007-1285-26-312-638</pub-id><pub-id pub-id-type="pmid">13106296</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953;26:638&#x02013;48.<pub-id pub-id-type="pmid">13106296</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Horsman</surname><given-names>MR</given-names></name><name><surname>Sorensen</surname><given-names>BS</given-names></name><name><surname>Busk</surname><given-names>M</given-names></name><name><surname>Siemann</surname><given-names>DW</given-names></name></person-group><article-title>Therapeutic modification of hypoxia</article-title><source>Clin Oncol (R Coll Radiol)</source><year>2021</year><volume>33</volume><fpage>e492</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1016/j.clon.2021.08.014</pub-id><pub-id pub-id-type="pmid">34535359</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Horsman MR, Sorensen BS, Busk M, Siemann DW. Therapeutic modification of hypoxia. Clin Oncol (R Coll Radiol). 2021;33:e492&#x02013;509.<pub-id pub-id-type="pmid">34535359</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Danhier</surname><given-names>P</given-names></name><name><surname>De Saedeleer</surname><given-names>CJ</given-names></name><name><surname>Karroum</surname><given-names>O</given-names></name><name><surname>De Preter</surname><given-names>G</given-names></name><name><surname>Porporato</surname><given-names>PE</given-names></name><name><surname>Jordan</surname><given-names>BF</given-names></name><etal/></person-group><article-title>Optimization of tumor radiotherapy with modulators of cell metabolism: toward clinical applications</article-title><source>Semin Radiat Oncol</source><year>2013</year><volume>23</volume><fpage>262</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.semradonc.2013.05.008</pub-id><pub-id pub-id-type="pmid">24012340</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Danhier P, De Saedeleer CJ, Karroum O, De Preter G, Porporato PE, Jordan BF, et al. Optimization of tumor radiotherapy with modulators of cell metabolism: toward clinical applications. Semin Radiat Oncol. 2013;23:262&#x02013;72.<pub-id pub-id-type="pmid">24012340</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Dewhirst MW, Stauffer PR, Das S, Craciunescu OI, Vujaskovic Z Hyperthermia. In: Gunderson LL, Tepper JE (eds) Clinical Radiation Oncology. 4th edn. (Elsevier, Philadelphia, PA, USA, 2016), pp 381&#x02013;98.</mixed-citation></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Liebl</surname><given-names>CM</given-names></name><name><surname>Kutschan</surname><given-names>S</given-names></name><name><surname>Dorfler</surname><given-names>J</given-names></name><name><surname>Kasmann</surname><given-names>L</given-names></name><name><surname>Hubner</surname><given-names>J</given-names></name></person-group><article-title>Systematic review about complementary medical hyperthermia in oncology</article-title><source>Clin Exp Med</source><year>2022</year><volume>22</volume><fpage>519</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1007/s10238-022-00846-9</pub-id><pub-id pub-id-type="pmid">35767077</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Liebl CM, Kutschan S, Dorfler J, Kasmann L, Hubner J. Systematic review about complementary medical hyperthermia in oncology. Clin Exp Med. 2022;22:519&#x02013;65.<pub-id pub-id-type="pmid">35767077</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Secomb</surname><given-names>TW</given-names></name><name><surname>Hsu</surname><given-names>R</given-names></name><name><surname>Ong</surname><given-names>ET</given-names></name><name><surname>Gross</surname><given-names>JF</given-names></name><name><surname>Dewhirst</surname><given-names>MW</given-names></name></person-group><article-title>Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors</article-title><source>Acta Oncol</source><year>1995</year><volume>34</volume><fpage>313</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.3109/02841869509093981</pub-id><pub-id pub-id-type="pmid">7779415</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Secomb TW, Hsu R, Ong ET, Gross JF, Dewhirst MW. Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol. 1995;34:313&#x02013;6.<pub-id pub-id-type="pmid">7779415</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Secomb</surname><given-names>TW</given-names></name><name><surname>Hsu</surname><given-names>R</given-names></name><name><surname>Dewhirst</surname><given-names>MW</given-names></name></person-group><article-title>Synergistic effects of hyperoxic gas breathing and reduced oxygen consumption on tumor oxygenation: a theoretical model</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2004</year><volume>59</volume><fpage>572</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2004.01.039</pub-id><pub-id pub-id-type="pmid">15145178</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Secomb TW, Hsu R, Dewhirst MW. Synergistic effects of hyperoxic gas breathing and reduced oxygen consumption on tumor oxygenation: a theoretical model. Int J Radiat Oncol Biol Phys. 2004;59:572&#x02013;8.<pub-id pub-id-type="pmid">15145178</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Dewhirst</surname><given-names>MW</given-names></name><name><surname>Navia</surname><given-names>IC</given-names></name><name><surname>Brizel</surname><given-names>DM</given-names></name><name><surname>Willett</surname><given-names>C</given-names></name><name><surname>Secomb</surname><given-names>TW</given-names></name></person-group><article-title>Multiple etiologies of tumor hypoxia require multifaceted solutions</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><fpage>375</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-2629</pub-id><pub-id pub-id-type="pmid">17255256</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Dewhirst MW, Navia IC, Brizel DM, Willett C, Secomb TW. Multiple etiologies of tumor hypoxia require multifaceted solutions. Clin Cancer Res. 2007;13:375&#x02013;7.<pub-id pub-id-type="pmid">17255256</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>d&#x02019;Hose</surname><given-names>D</given-names></name><name><surname>Mathieu</surname><given-names>B</given-names></name><name><surname>Mignion</surname><given-names>L</given-names></name><name><surname>Hardy</surname><given-names>M</given-names></name><name><surname>Ouari</surname><given-names>O</given-names></name><name><surname>Jordan</surname><given-names>BF</given-names></name><etal/></person-group><article-title>EPR investigations to study the impact of mito-Metformin on the mitochondrial function of prostate cancer cells</article-title><source>Molecules</source><year>2022</year><volume>27</volume><fpage>5872</fpage><pub-id pub-id-type="doi">10.3390/molecules27185872</pub-id><pub-id pub-id-type="pmid">36144606</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">d&#x02019;Hose D, Mathieu B, Mignion L, Hardy M, Ouari O, Jordan BF, et al. EPR investigations to study the impact of mito-Metformin on the mitochondrial function of prostate cancer cells. Molecules. 2022;27:5872.<pub-id pub-id-type="pmid">36144606</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Gallez</surname><given-names>B</given-names></name><name><surname>Neveu</surname><given-names>MA</given-names></name><name><surname>Danhier</surname><given-names>P</given-names></name><name><surname>Jordan</surname><given-names>BF</given-names></name></person-group><article-title>Manipulation of tumor oxygenation and radiosensitivity through modification of cell respiration. A critical review of approaches and imaging biomarkers for therapeutic guidance</article-title><source>Biochim Biophys Acta Bioenerg</source><year>2017</year><volume>1858</volume><fpage>700</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.bbabio.2017.01.002</pub-id><pub-id pub-id-type="pmid">28088332</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Gallez B, Neveu MA, Danhier P, Jordan BF. Manipulation of tumor oxygenation and radiosensitivity through modification of cell respiration. A critical review of approaches and imaging biomarkers for therapeutic guidance. Biochim Biophys Acta Bioenerg. 2017;1858:700&#x02013;11.<pub-id pub-id-type="pmid">28088332</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>d&#x02019;Hose</surname><given-names>D</given-names></name><name><surname>Mignion</surname><given-names>L</given-names></name><name><surname>Hamelin</surname><given-names>L</given-names></name><name><surname>Sonveaux</surname><given-names>P</given-names></name><name><surname>Jordan</surname><given-names>BF</given-names></name><name><surname>Gallez</surname><given-names>B</given-names></name></person-group><article-title>Statins alleviate tumor hypoxia in prostate cancer models by decreasing oxygen consumption: An opportunity for radiosensitization?</article-title><source>Biomolecules</source><year>2022</year><volume>12</volume><fpage>1418</fpage><pub-id pub-id-type="doi">10.3390/biom12101418</pub-id><pub-id pub-id-type="pmid">36291627</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">d&#x02019;Hose D, Mignion L, Hamelin L, Sonveaux P, Jordan BF, Gallez B. Statins alleviate tumor hypoxia in prostate cancer models by decreasing oxygen consumption: An opportunity for radiosensitization? Biomolecules. 2022;12:1418.<pub-id pub-id-type="pmid">36291627</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Porporato</surname><given-names>PE</given-names></name><name><surname>Payen</surname><given-names>VL</given-names></name><name><surname>Perez-Escuredo</surname><given-names>J</given-names></name><name><surname>De Saedeleer</surname><given-names>CJ</given-names></name><name><surname>Danhier</surname><given-names>P</given-names></name><name><surname>Copetti</surname><given-names>T</given-names></name><etal/></person-group><article-title>A mitochondrial switch promotes tumor metastasis</article-title><source>Cell Rep</source><year>2014</year><volume>8</volume><fpage>754</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.06.043</pub-id><pub-id pub-id-type="pmid">25066121</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Porporato PE, Payen VL, Perez-Escuredo J, De Saedeleer CJ, Danhier P, Copetti T, et al. A mitochondrial switch promotes tumor metastasis. Cell Rep. 2014;8:754&#x02013;66.<pub-id pub-id-type="pmid">25066121</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Capeloa</surname><given-names>T</given-names></name><name><surname>Krzystyniak</surname><given-names>J</given-names></name><name><surname>Canas Rodriguez</surname><given-names>A</given-names></name><name><surname>Payen</surname><given-names>VL</given-names></name><name><surname>Zampieri</surname><given-names>LX</given-names></name><name><surname>Pranzini</surname><given-names>E</given-names></name><etal/></person-group><article-title>MitoQ prevents human breast cancer recurrence and lung metastasis in mice</article-title><source>Cancers (Basel)</source><year>2022</year><volume>15</volume><fpage>1488</fpage><pub-id pub-id-type="doi">10.3390/cancers14061488</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Capeloa T, Krzystyniak J, Canas Rodriguez A, Payen VL, Zampieri LX, Pranzini E, et al. MitoQ prevents human breast cancer recurrence and lung metastasis in mice. Cancers (Basel). 2022;15:1488.</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Capeloa</surname><given-names>T</given-names></name><name><surname>Krzystyniak</surname><given-names>J</given-names></name><name><surname>d&#x02019;Hose</surname><given-names>D</given-names></name><name><surname>Canas Rodriguez</surname><given-names>A</given-names></name><name><surname>Payen</surname><given-names>VL</given-names></name><name><surname>Zampieri</surname><given-names>LX</given-names></name><etal/></person-group><article-title>MitoQ inhibits human breast cancer cell migration, invasion and clonogenicity</article-title><source>Cancers (Basel)</source><year>2022</year><volume>14</volume><fpage>1516</fpage><pub-id pub-id-type="doi">10.3390/cancers14061516</pub-id><pub-id pub-id-type="pmid">35326667</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Capeloa T, Krzystyniak J, d&#x02019;Hose D, Canas Rodriguez A, Payen VL, Zampieri LX, et al. MitoQ inhibits human breast cancer cell migration, invasion and clonogenicity. Cancers (Basel). 2022;14:1516.<pub-id pub-id-type="pmid">35326667</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Capeloa</surname><given-names>T</given-names></name><name><surname>Van de Velde</surname><given-names>JA</given-names></name><name><surname>d&#x02019;Hose</surname><given-names>D</given-names></name><name><surname>Lipari</surname><given-names>SG</given-names></name><name><surname>Derouane</surname><given-names>F</given-names></name><name><surname>Hamelin</surname><given-names>L</given-names></name><etal/></person-group><article-title>Inhibition of mitochondrial redox signaling with MitoQ prevents metastasis of human pancreatic cancer in mice</article-title><source>Cancers (Basel)</source><year>2022</year><volume>14</volume><fpage>4918</fpage><pub-id pub-id-type="doi">10.3390/cancers14194918</pub-id><pub-id pub-id-type="pmid">36230841</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Capeloa T, Van de Velde JA, d&#x02019;Hose D, Lipari SG, Derouane F, Hamelin L, et al. Inhibition of mitochondrial redox signaling with MitoQ prevents metastasis of human pancreatic cancer in mice. Cancers (Basel). 2022;14:4918.<pub-id pub-id-type="pmid">36230841</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>RA</given-names></name><name><surname>Murphy</surname><given-names>MP</given-names></name></person-group><article-title>Mitochondria-targeted antioxidants as therapies</article-title><source>Discov Med</source><year>2011</year><volume>11</volume><fpage>106</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">21356165</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Smith RA, Murphy MP. Mitochondria-targeted antioxidants as therapies. Discov Med. 2011;11:106&#x02013;14.<pub-id pub-id-type="pmid">21356165</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Skulachev</surname><given-names>VP</given-names></name><name><surname>Vyssokikh</surname><given-names>MY</given-names></name><name><surname>Chernyak</surname><given-names>BV</given-names></name><name><surname>Mulkidjanian</surname><given-names>AY</given-names></name><name><surname>Skulachev</surname><given-names>MV</given-names></name><name><surname>Shilovsky</surname><given-names>GA</given-names></name><etal/></person-group><article-title>Six functions of respiration: Isn&#x02019;t it time to take control over ROS production in mitochondria, and aging along with it?</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><fpage>12540</fpage><pub-id pub-id-type="doi">10.3390/ijms241612540</pub-id><pub-id pub-id-type="pmid">37628720</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Skulachev VP, Vyssokikh MY, Chernyak BV, Mulkidjanian AY, Skulachev MV, Shilovsky GA, et al. Six functions of respiration: Isn&#x02019;t it time to take control over ROS production in mitochondria, and aging along with it? Int J Mol Sci. 2023;24:12540.<pub-id pub-id-type="pmid">37628720</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Zinovkin</surname><given-names>RA</given-names></name><name><surname>Lyamzaev</surname><given-names>KG</given-names></name><name><surname>Chernyak</surname><given-names>BV</given-names></name></person-group><article-title>Current perspectives of mitochondria-targeted antioxidants in cancer prevention and treatment</article-title><source>Front Cell Dev Biol</source><year>2023</year><volume>11</volume><fpage>1048177</fpage><pub-id pub-id-type="doi">10.3389/fcell.2023.1048177</pub-id><pub-id pub-id-type="pmid">37009472</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Zinovkin RA, Lyamzaev KG, Chernyak BV. Current perspectives of mitochondria-targeted antioxidants in cancer prevention and treatment. Front Cell Dev Biol. 2023;11:1048177.<pub-id pub-id-type="pmid">37009472</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>MP</given-names></name></person-group><article-title>Understanding and preventing mitochondrial oxidative damage</article-title><source>Biochem Soc Trans</source><year>2016</year><volume>44</volume><fpage>1219</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1042/BST20160108</pub-id><pub-id pub-id-type="pmid">27911703</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Murphy MP. Understanding and preventing mitochondrial oxidative damage. Biochem Soc Trans. 2016;44:1219&#x02013;26.<pub-id pub-id-type="pmid">27911703</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>MF</given-names></name><name><surname>Kelso</surname><given-names>GF</given-names></name><name><surname>Blaikie</surname><given-names>FH</given-names></name><name><surname>James</surname><given-names>AM</given-names></name><name><surname>Cochem&#x000e9;</surname><given-names>HM</given-names></name><name><surname>Filipovska</surname><given-names>A</given-names></name><etal/></person-group><article-title>Lipophilic triphenylphosphonium cations as tools in mitochondrial bioenergetics and free radical biology</article-title><source>Biochemistry (Mosc)</source><year>2005</year><volume>70</volume><fpage>222</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1007/s10541-005-0104-5</pub-id><pub-id pub-id-type="pmid">15807662</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Ross MF, Kelso GF, Blaikie FH, James AM, Cochem&#x000e9; HM, Filipovska A, et al. Lipophilic triphenylphosphonium cations as tools in mitochondrial bioenergetics and free radical biology. Biochemistry (Mosc). 2005;70:222&#x02013;30.<pub-id pub-id-type="pmid">15807662</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>MF</given-names></name><name><surname>Prime</surname><given-names>TA</given-names></name><name><surname>Abakumova</surname><given-names>I</given-names></name><name><surname>James</surname><given-names>AM</given-names></name><name><surname>Porteous</surname><given-names>CM</given-names></name><name><surname>Smith</surname><given-names>RAJ</given-names></name><etal/></person-group><article-title>Rapid and extensive uptake and activation of hydrophobic triphenylphosphonium cations within cells</article-title><source>Biochem J</source><year>2008</year><volume>411</volume><fpage>633</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1042/BJ20080063</pub-id><pub-id pub-id-type="pmid">18294140</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Ross MF, Prime TA, Abakumova I, James AM, Porteous CM, Smith RAJ, et al. Rapid and extensive uptake and activation of hydrophobic triphenylphosphonium cations within cells. Biochem J. 2008;411:633&#x02013;45.<pub-id pub-id-type="pmid">18294140</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Asin-Cayuela</surname><given-names>J</given-names></name><name><surname>Manas</surname><given-names>AR</given-names></name><name><surname>James</surname><given-names>AM</given-names></name><name><surname>Smith</surname><given-names>RA</given-names></name><name><surname>Murphy</surname><given-names>MP</given-names></name></person-group><article-title>Fine-tuning the hydrophobicity of a mitochondria-targeted antioxidant</article-title><source>FEBS Lett</source><year>2004</year><volume>571</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2004.06.045</pub-id><pub-id pub-id-type="pmid">15280009</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Asin-Cayuela J, Manas AR, James AM, Smith RA, Murphy MP. Fine-tuning the hydrophobicity of a mitochondria-targeted antioxidant. FEBS Lett. 2004;571:9&#x02013;16.<pub-id pub-id-type="pmid">15280009</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>AM</given-names></name><name><surname>Sharpley</surname><given-names>MS</given-names></name><name><surname>Manas</surname><given-names>AR</given-names></name><name><surname>Frerman</surname><given-names>FE</given-names></name><name><surname>Hirst</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Interaction of the mitochondria-targeted antioxidant MitoQ with phospholipid bilayers and ubiquinone oxidoreductases</article-title><source>J Biol Chem</source><year>2007</year><volume>282</volume><fpage>14708</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1074/jbc.M611463200</pub-id><pub-id pub-id-type="pmid">17369262</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">James AM, Sharpley MS, Manas AR, Frerman FE, Hirst J, Smith RA, et al. Interaction of the mitochondria-targeted antioxidant MitoQ with phospholipid bilayers and ubiquinone oxidoreductases. J Biol Chem. 2007;282:14708&#x02013;18.<pub-id pub-id-type="pmid">17369262</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Rondeau</surname><given-names>JD</given-names></name><name><surname>Van de Velde</surname><given-names>JA</given-names></name><name><surname>Bouidida</surname><given-names>Y</given-names></name><name><surname>Sonveaux</surname><given-names>P</given-names></name></person-group><article-title>Subclinical dose irradiation triggers human breast cancer migration via mitochondrial reactive oxygen species</article-title><source>Cancer Metab</source><year>2024</year><volume>12</volume><fpage>20</fpage><pub-id pub-id-type="doi">10.1186/s40170-024-00347-1</pub-id><pub-id pub-id-type="pmid">38978126</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Rondeau JD, Van de Velde JA, Bouidida Y, Sonveaux P. Subclinical dose irradiation triggers human breast cancer migration via mitochondrial reactive oxygen species. Cancer Metab. 2024;12:20.<pub-id pub-id-type="pmid">38978126</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>RA</given-names></name><name><surname>Murphy</surname><given-names>MP</given-names></name></person-group><article-title>Animal and human studies with the mitochondria-targeted antioxidant MitoQ</article-title><source>Ann N Y Acad Sci</source><year>2010</year><volume>1201</volume><fpage>96</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2010.05627.x</pub-id><pub-id pub-id-type="pmid">20649545</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Smith RA, Murphy MP. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann N Y Acad Sci. 2010;1201:96&#x02013;103.<pub-id pub-id-type="pmid">20649545</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Farabegoli</surname><given-names>F</given-names></name><name><surname>Vettraino</surname><given-names>M</given-names></name><name><surname>Manerba</surname><given-names>M</given-names></name><name><surname>Fiume</surname><given-names>L</given-names></name><name><surname>Roberti</surname><given-names>M</given-names></name><name><surname>Di Stefano</surname><given-names>G</given-names></name></person-group><article-title>Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways</article-title><source>Eur J Pharm Sci</source><year>2012</year><volume>47</volume><fpage>729</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2012.08.012</pub-id><pub-id pub-id-type="pmid">22954722</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Farabegoli F, Vettraino M, Manerba M, Fiume L, Roberti M, Di Stefano G. Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways. Eur J Pharm Sci. 2012;47:729&#x02013;38.<pub-id pub-id-type="pmid">22954722</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Sonveaux</surname><given-names>P</given-names></name><name><surname>Vegran</surname><given-names>F</given-names></name><name><surname>Schroeder</surname><given-names>T</given-names></name><name><surname>Wergin</surname><given-names>MC</given-names></name><name><surname>Verrax</surname><given-names>J</given-names></name><name><surname>Rabbani</surname><given-names>ZN</given-names></name><etal/></person-group><article-title>Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice</article-title><source>J Clin Invest</source><year>2008</year><volume>118</volume><fpage>3930</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">19033663</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest. 2008;118:3930&#x02013;42.<pub-id pub-id-type="pmid">19033663</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Cacace</surname><given-names>A</given-names></name><name><surname>Sboarina</surname><given-names>M</given-names></name><name><surname>Vazeille</surname><given-names>T</given-names></name><name><surname>Sonveaux</surname><given-names>P</given-names></name></person-group><article-title>Glutamine activates STAT3 to control cancer cell proliferation independently of glutamine metabolism</article-title><source>Oncogene</source><year>2017</year><volume>36</volume><fpage>2074</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1038/onc.2016.364</pub-id><pub-id pub-id-type="pmid">27748760</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Cacace A, Sboarina M, Vazeille T, Sonveaux P. Glutamine activates STAT3 to control cancer cell proliferation independently of glutamine metabolism. Oncogene. 2017;36:2074&#x02013;84.<pub-id pub-id-type="pmid">27748760</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Skulachev</surname><given-names>VP</given-names></name></person-group><article-title>How to clean the dirtiest place in the cell: cationic antioxidants as intramitochondrial ROS scavengers</article-title><source>IUBMB Life</source><year>2005</year><volume>57</volume><fpage>305</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1080/15216540500092161</pub-id><pub-id pub-id-type="pmid">16036614</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Skulachev VP. How to clean the dirtiest place in the cell: cationic antioxidants as intramitochondrial ROS scavengers. IUBMB Life. 2005;57:305&#x02013;10.<pub-id pub-id-type="pmid">16036614</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Dosey</surname><given-names>TL</given-names></name><name><surname>Biechele</surname><given-names>T</given-names></name><name><surname>Moon</surname><given-names>RT</given-names></name><name><surname>Horwitz</surname><given-names>MS</given-names></name><name><surname>Ruohola-Baker</surname><given-names>H</given-names></name></person-group><article-title>Assessment of hypoxia inducible factor levels in cancer cell lines upon hypoxic induction using a novel reporter construct</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e27460</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0027460</pub-id><pub-id pub-id-type="pmid">22132102</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Zhou W, Dosey TL, Biechele T, Moon RT, Horwitz MS, Ruohola-Baker H. Assessment of hypoxia inducible factor levels in cancer cell lines upon hypoxic induction using a novel reporter construct. PLoS One. 2011;6:e27460.<pub-id pub-id-type="pmid">22132102</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Benton</surname><given-names>G</given-names></name><name><surname>DeGray</surname><given-names>G</given-names></name><name><surname>Kleinman</surname><given-names>HK</given-names></name><name><surname>George</surname><given-names>J</given-names></name><name><surname>Arnaoutova</surname><given-names>I</given-names></name></person-group><article-title>In vitro microtumors provide a physiologically predictive tool for breast cancer therapeutic screening</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><fpage>e0123312</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0123312</pub-id><pub-id pub-id-type="pmid">25856378</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Benton G, DeGray G, Kleinman HK, George J, Arnaoutova I. In vitro microtumors provide a physiologically predictive tool for breast cancer therapeutic screening. PLoS One. 2015;10:e0123312.<pub-id pub-id-type="pmid">25856378</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>EL</given-names></name><name><surname>Chandel</surname><given-names>NS</given-names></name></person-group><article-title>Mitochondrial oxygen sensing: Regulation of hypoxia-inducible factor by mitochondrial generated reactive oxygen species</article-title><source>Essays Biochem</source><year>2007</year><volume>43</volume><fpage>17</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1042/bse0430017</pub-id><pub-id pub-id-type="pmid">17705790</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Bell EL, Chandel NS. Mitochondrial oxygen sensing: Regulation of hypoxia-inducible factor by mitochondrial generated reactive oxygen species. Essays Biochem. 2007;43:17&#x02013;27.<pub-id pub-id-type="pmid">17705790</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Pouyssegur</surname><given-names>J</given-names></name><name><surname>Mechta-Grigoriou</surname><given-names>F</given-names></name></person-group><article-title>Redox regulation of the hypoxia-inducible factor</article-title><source>Biol Chem</source><year>2006</year><volume>387</volume><fpage>1337</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1515/BC.2006.167</pub-id><pub-id pub-id-type="pmid">17081104</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Pouyssegur J, Mechta-Grigoriou F. Redox regulation of the hypoxia-inducible factor. Biol Chem. 2006;387:1337&#x02013;46.<pub-id pub-id-type="pmid">17081104</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Sonveaux</surname><given-names>P</given-names></name><name><surname>Copetti</surname><given-names>T</given-names></name><name><surname>De Saedeleer</surname><given-names>CJ</given-names></name><name><surname>Vegran</surname><given-names>F</given-names></name><name><surname>Verrax</surname><given-names>J</given-names></name><name><surname>Kennedy</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e33418</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0033418</pub-id><pub-id pub-id-type="pmid">22428047</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Sonveaux P, Copetti T, De Saedeleer CJ, Vegran F, Verrax J, Kennedy KM, et al. Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS One. 2012;7:e33418.<pub-id pub-id-type="pmid">22428047</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Tauskela</surname><given-names>JS</given-names></name></person-group><article-title>MitoQ-a mitochondria-targeted antioxidant</article-title><source>IDrugs</source><year>2007</year><volume>10</volume><fpage>399</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">17642004</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Tauskela JS. MitoQ-a mitochondria-targeted antioxidant. IDrugs. 2007;10:399&#x02013;412.<pub-id pub-id-type="pmid">17642004</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Di</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Mi</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>MitoQ regulates autophagy by inducing a pseudo-mitochondrial membrane potential</article-title><source>Autophagy</source><year>2017</year><volume>13</volume><fpage>730</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1080/15548627.2017.1280219</pub-id><pub-id pub-id-type="pmid">28121478</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Sun C, Liu X, Di C, Wang Z, Mi X, Liu Y, et al. MitoQ regulates autophagy by inducing a pseudo-mitochondrial membrane potential. Autophagy. 2017;13:730&#x02013;8.<pub-id pub-id-type="pmid">28121478</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><etal/></person-group><article-title>Mitochondrial-targeted antioxidant MitoQ-mediated autophagy: A novel strategy for precise radiation protection</article-title><source>Antioxidants (Basel)</source><year>2023</year><volume>12</volume><fpage>437</fpage><pub-id pub-id-type="pmid">36829996</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Bao X, Liu X, Wu Q, Ye F, Shi Z, Xu D, et al. Mitochondrial-targeted antioxidant MitoQ-mediated autophagy: A novel strategy for precise radiation protection. Antioxidants (Basel). 2023;12:437.<pub-id pub-id-type="pmid">36829996</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Dawoud</surname><given-names>M</given-names></name><name><surname>Attallah</surname><given-names>KM</given-names></name><name><surname>Ibrahim</surname><given-names>IT</given-names></name><name><surname>Karam</surname><given-names>HM</given-names></name><name><surname>Ibrahim</surname><given-names>AA</given-names></name></person-group><article-title>MitoQ and its hyaluronic acid-based nanopreparation mitigating gamma radiation-induced intestinal injury in mice: alleviation of oxidative stress and apoptosis</article-title><source>Naunyn Schmiedebergs Arch Pharmacol</source><year>2024</year><volume>397</volume><fpage>5193</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1007/s00210-024-02948-5</pub-id><pub-id pub-id-type="pmid">38252300</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Dawoud M, Attallah KM, Ibrahim IT, Karam HM, Ibrahim AA. MitoQ and its hyaluronic acid-based nanopreparation mitigating gamma radiation-induced intestinal injury in mice: alleviation of oxidative stress and apoptosis. Naunyn Schmiedebergs Arch Pharmacol. 2024;397:5193&#x02013;205.<pub-id pub-id-type="pmid">38252300</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>AA</given-names></name><name><surname>Karam</surname><given-names>HM</given-names></name><name><surname>Shaaban</surname><given-names>EA</given-names></name><name><surname>Safar</surname><given-names>MM</given-names></name><name><surname>El-Yamany</surname><given-names>MF</given-names></name></person-group><article-title>MitoQ ameliorates testicular damage induced by gamma irradiation in rats: Modulation of mitochondrial apoptosis and steroidogenesis</article-title><source>Life Sci</source><year>2019</year><volume>232</volume><fpage>116655</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2019.116655</pub-id><pub-id pub-id-type="pmid">31306659</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Ibrahim AA, Karam HM, Shaaban EA, Safar MM, El-Yamany MF. MitoQ ameliorates testicular damage induced by gamma irradiation in rats: Modulation of mitochondrial apoptosis and steroidogenesis. Life Sci. 2019;232:116655.<pub-id pub-id-type="pmid">31306659</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>RM</given-names></name><name><surname>Fok</surname><given-names>M</given-names></name><name><surname>Grundy</surname><given-names>G</given-names></name><name><surname>Parsons</surname><given-names>JL</given-names></name><name><surname>Rocha</surname><given-names>S</given-names></name></person-group><article-title>The role of autophagy in hypoxia-induced radioresistance</article-title><source>Radiother Oncol</source><year>2023</year><volume>189</volume><fpage>109951</fpage><pub-id pub-id-type="doi">10.1016/j.radonc.2023.109951</pub-id><pub-id pub-id-type="pmid">37838322</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Hill RM, Fok M, Grundy G, Parsons JL, Rocha S. The role of autophagy in hypoxia-induced radioresistance. Radiother Oncol. 2023;189:109951.<pub-id pub-id-type="pmid">37838322</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Dashdorj</surname><given-names>A</given-names></name><name><surname>Jyothi</surname><given-names>KR</given-names></name><name><surname>Lim</surname><given-names>S</given-names></name><name><surname>Jo</surname><given-names>A</given-names></name><name><surname>Nguyen</surname><given-names>MN</given-names></name><name><surname>Ha</surname><given-names>J</given-names></name><etal/></person-group><article-title>Mitochondria-targeted antioxidant MitoQ ameliorates experimental mouse colitis by suppressing NLRP3 inflammasome-mediated inflammatory cytokines</article-title><source>BMC Med</source><year>2013</year><volume>11</volume><fpage>178</fpage><pub-id pub-id-type="doi">10.1186/1741-7015-11-178</pub-id><pub-id pub-id-type="pmid">23915129</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Dashdorj A, Jyothi KR, Lim S, Jo A, Nguyen MN, Ha J, et al. Mitochondria-targeted antioxidant MitoQ ameliorates experimental mouse colitis by suppressing NLRP3 inflammasome-mediated inflammatory cytokines. BMC Med. 2013;11:178.<pub-id pub-id-type="pmid">23915129</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Mitoquinone alleviates osteoarthritis progress by activating the NRF2-Parkin axis</article-title><source>iScience</source><year>2023</year><volume>26</volume><fpage>107647</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2023.107647</pub-id><pub-id pub-id-type="pmid">37694150</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Hou L, Wang G, Zhang X, Lu F, Xu J, Guo Z, et al. Mitoquinone alleviates osteoarthritis progress by activating the NRF2-Parkin axis. iScience. 2023;26:107647.<pub-id pub-id-type="pmid">37694150</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Kelso</surname><given-names>GF</given-names></name><name><surname>Porteous</surname><given-names>CM</given-names></name><name><surname>Coulter</surname><given-names>CV</given-names></name><name><surname>Hughes</surname><given-names>G</given-names></name><name><surname>Porteous</surname><given-names>WK</given-names></name><name><surname>Ledgerwood</surname><given-names>EC</given-names></name><etal/></person-group><article-title>Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>4588</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1074/jbc.M009093200</pub-id><pub-id pub-id-type="pmid">11092892</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem. 2001;276:4588&#x02013;96.<pub-id pub-id-type="pmid">11092892</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Beckers</surname><given-names>C</given-names></name><name><surname>Vasilikos</surname><given-names>L</given-names></name><name><surname>Sanchez Fernandez</surname><given-names>A</given-names></name><name><surname>Moor</surname><given-names>L</given-names></name><name><surname>Pruschy</surname><given-names>M</given-names></name></person-group><article-title>Targeting the survival kinase DYRK1B: A novel approach to overcome radiotherapy-related treatment resistance</article-title><source>Radiother Oncol</source><year>2024</year><volume>190</volume><fpage>110039</fpage><pub-id pub-id-type="doi">10.1016/j.radonc.2023.110039</pub-id><pub-id pub-id-type="pmid">38040123</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Beckers C, Vasilikos L, Sanchez Fernandez A, Moor L, Pruschy M. Targeting the survival kinase DYRK1B: A novel approach to overcome radiotherapy-related treatment resistance. Radiother Oncol. 2024;190:110039.<pub-id pub-id-type="pmid">38040123</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>